Literature DB >> 10065349

Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts.

S Spireas1, T Wang, R Grover.   

Abstract

The effects of powder substrate composition on the in vitro release properties of methyclothiazide liquisolid compacts were evaluated. The dissolution patterns of this water-insoluble drug formulated in liquisolid tablets were also compared to those of commercial products. According to the new liquisolid technique, liquid medications such as solutions or suspensions of water-insoluble drugs in suitable nonvolatile liquid vehicles can be converted into acceptably flowing and readily compressible powders by a simple admixture with certain powder substrates, which are selected powders referred to as the carrier and coating materials. Enhanced release profiles may be exhibited by such systems due to the increased wetting properties and surface of drug available for dissolution. Liquisolid tablets of methyclothiazide containing a 5% w/w drug solution in polyethylene glycol 400 were prepared using powder substrates of different excipient ratios. The release rates of such products were assessed using the USP dissolution test and were compared to those of their commercial counterparts. It was observed that maximum drug dissolution rates can be exhibited by systems that have powder substrates with optimum carrier-to-coating ratios. In addition, liquisolid tablets displayed significantly enhanced dissolution profiles compared to those of marketed products.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065349     DOI: 10.1081/ddc-100102156

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  10 in total

Review 1.  The science of USP 1 and 2 dissolution: present challenges and future relevance.

Authors:  Vivian Gray; Gregg Kelly; Min Xia; Chris Butler; Saji Thomas; Stephen Mayock
Journal:  Pharm Res       Date:  2009-01-23       Impact factor: 4.200

2.  Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release.

Authors:  Mazen El-Hammadi; Nisrine Awad
Journal:  AAPS PharmSciTech       Date:  2011-11-19       Impact factor: 3.246

3.  Enhancement of Loperamide Dissolution Rate by Liquisolid Compact Technique.

Authors:  Kambham Venkateswarlu; Jami Komala Preethi; Kothapalli Bonnoth Chandrasekhar
Journal:  Adv Pharm Bull       Date:  2016-09-25

4.  Design and Development of Solid SMEDDS and Liquisolid Formulations of Lovastatin, for Improved Drug Dissolution and In vivo Effects-a Pharmacokinetic and Pharmacodynamic Assessment.

Authors:  Dinesh Suram; Kishan Veerabrahma
Journal:  AAPS PharmSciTech       Date:  2022-04-22       Impact factor: 3.246

5.  Application of liquisolid technology for enhancing solubility and dissolution of rosuvastatin.

Authors:  Pavan Ram Kamble; Karimunnisa Sameer Shaikh; Pravin Digambar Chaudhari
Journal:  Adv Pharm Bull       Date:  2013-12-24

6.  Liquisolid systems to improve the dissolution of furosemide.

Authors:  Babatunde Akinlade; Amal A Elkordy; Ebtessam A Essa; Sahar Elhagar
Journal:  Sci Pharm       Date:  2010-04-23

7.  Liquisolid Tablets for Dissolution Enhancement of a Hypolipidemic Drug.

Authors:  D S Patel; R M Pipaliya; Naazneen Surti
Journal:  Indian J Pharm Sci       Date:  2015 May-Jun       Impact factor: 0.975

8.  Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan.

Authors:  Naveen Chella; Nataraj Narra; Tadikonda Rama Rao
Journal:  J Drug Deliv       Date:  2014-10-12

9.  Liquigroud technique: a new concept for enhancing dissolution rate of glibenclamide by combination of liquisolid and co-grinding technologies.

Authors:  Leila Azharshekoufeh; Javad Shokri; Mohammad Barzegar-Jalali; Yousef Javadzadeh
Journal:  Bioimpacts       Date:  2017-02-28

10.  Enhancement of dissolution rate of indomethacin: using liquisolid compacts.

Authors:  Majid Saeedi; Jafar Akbari; Katayoun Morteza-Semnani; Reza Enayati-Fard; Shirin Sar-Reshteh-Dar; Ala Soleymani
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.